Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Impact of vaccine delays at the 2, 4, 6 and 12 month visits on incomplete vaccination status by 24 months of age in Quebec, Canada.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Sauvageau C, De Serres G.

BMC Public Health. 2018 Dec 11;18(1):1364. doi: 10.1186/s12889-018-6235-6.

2.

Application of the Test-Negative Design to General Laboratory Submissions.

Skowronski DM, De Serres G.

JAMA Pediatr. 2018 Dec 10. doi: 10.1001/jamapediatrics.2018.4370. [Epub ahead of print] No abstract available.

PMID:
30535171
3.

Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.

De Serres G, Billard MN, Gariépy MC, Rouleau I, Toth E, Landry M, Boulianne N, Gagné H, Gilca V, Deceuninck G, Ouakki M, Skowronski DM.

Vaccine. 2018 Dec 18;36(52):8039-8046. doi: 10.1016/j.vaccine.2018.10.095. Epub 2018 Nov 19.

PMID:
30467063
4.

Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9.

PMID:
30314913
5.

Vaccine effectiveness against lineage matched and mismatched influenza B viruses across 8 seasons in Canada, 2010-11 to 2017-18.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Fonseca K, Charest H, Martineau C, Hickman R, Chan T, Jassem A, Petric M, Rose C, Bastien N, Li Y, Krajden M.

Clin Infect Dis. 2018 Oct 11. doi: 10.1093/cid/ciy876. [Epub ahead of print]

PMID:
30312364
6.

Investigation of an increase in large local reactions following vaccine schedule change to include DTaP-HB-IPV-Hib (Infanrix-hexa®) and MMRV (ProQuad®) at 18 months of age.

Kiely M, Billard MN, Toth E, Zafack JG, Landry M, Skowronski DM, De Serres G.

Vaccine. 2018 Oct 29;36(45):6688-6694. doi: 10.1016/j.vaccine.2018.09.049. Epub 2018 Sep 27.

PMID:
30269915
7.

Should Sex Be Considered an Effect Modifier in the Evaluation of Influenza Vaccine Effectiveness?

Chambers C, Skowronski DM, Rose C, Serres G, Winter AL, Dickinson JA, Jassem A, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Petric M, Krajden M.

Open Forum Infect Dis. 2018 Sep 4;5(9):ofy211. doi: 10.1093/ofid/ofy211. eCollection 2018 Sep.

8.

Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.

Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER.

Hum Vaccin Immunother. 2018 Sep 25:1-5. doi: 10.1080/21645515.2018.1522469. [Epub ahead of print]

PMID:
30252583
9.

Rate of Recurrence of Adverse Events Following Immunization: Results of 19 Years of Surveillance Ii Quebec, Canada.

Zafack JG, Toth E, Landry M, Drolet JP, Top KA, De Serres G.

Pediatr Infect Dis J. 2018 Sep 10. doi: 10.1097/INF.0000000000002162. [Epub ahead of print]

PMID:
30204662
10.

Impact of the addition of new vaccines in the early childhood schedule on vaccine coverage by 24 months of age from 2006 to 2016 in Quebec, Canada.

Kiely M, Boulianne N, Talbot D, Ouakki M, Guay M, Landry M, Zafack J, Sauvageau C, De Serres G.

Vaccine. 2018 Jul 5;36(29):4383-4391. doi: 10.1016/j.vaccine.2018.03.085. Epub 2018 Jun 7.

PMID:
29887321
11.

Ecological Fallacy, Nonspecific Outcomes, and the Attribution of Disproportionate Vaccine Benefits.

De Serres G, Skowronski DM.

Clin Infect Dis. 2018 May 17;66(11):1817-1818. doi: 10.1093/cid/ciy014. No abstract available.

12.

Role of Egg-adaptation Mutations in Low Influenza A(H3N2) Vaccine Effectiveness During the 2012-2013 Season.

Skowronski DM, De Serres G.

Clin Infect Dis. 2018 Oct 15;67(9):1474-1476. doi: 10.1093/cid/ciy350. No abstract available.

13.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Skowronski DM, Chambers C, De Serres G, Dickinson JA, Winter AL, Hickman R, Chan T, Jassem AN, Drews SJ, Charest H, Gubbay JB, Bastien N, Li Y, Krajden M.

Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035.

14.

Delayed measles vaccination of toddlers in Canada: Associated socio-demographic factors and parental knowledge, attitudes and beliefs.

Périnet S, Kiely M, De Serres G, Gilbert NL.

Hum Vaccin Immunother. 2018 Apr 3;14(4):868-874. doi: 10.1080/21645515.2017.1412899. Epub 2018 Jan 16.

15.

Selection Bias in the Assessment of Frailty and Its Role in Influenza Vaccine Effectiveness Evaluation Among Elderly Adults.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Dec 27;217(1):168. doi: 10.1093/infdis/jix548. No abstract available.

PMID:
29045721
16.

Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay JB, Drews SJ, Martineau C, Charest H, Krajden M, Bastien N, Li Y.

J Infect Dis. 2017 Dec 19;216(12):1487-1500. doi: 10.1093/infdis/jix526.

17.

Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.

Billard MN, De Serres G, Gariépy MC, Boulianne N, Toth E, Landry M, Skowronski DM.

PLoS One. 2017 Oct 11;12(10):e0186070. doi: 10.1371/journal.pone.0186070. eCollection 2017.

18.

Absence of association between Guillain-Barré syndrome hospitalizations and HPV-vaccine.

Deceuninck G, Sauvageau C, Gilca V, Boulianne N, De Serres G.

Expert Rev Vaccines. 2018 Jan;17(1):99-102. doi: 10.1080/14760584.2018.1388168. Epub 2017 Oct 13.

PMID:
28972438
19.

Age-Related Differences in Influenza B Infection by Lineage in a Community-Based Sentinel System, 2010-2011 to 2015-2016, Canada.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y.

J Infect Dis. 2017 Sep 15;216(6):697-702. doi: 10.1093/infdis/jix393.

20.

Risk of Recurrence of Adverse Events Following Immunization: A Systematic Review.

Zafack JG, De Serres G, Kiely M, Gariépy MC, Rouleau I, Top KA; Canadian Immunization Research Network .

Pediatrics. 2017 Sep;140(3). pii: e20163707. doi: 10.1542/peds.2016-3707. Review.

21.

Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons.

Boikos C, Joseph L, Scheifele D, Lands LC, De Serres G, Papenburg J, Winters N, Chilvers M, Quach C.

Vaccine. 2017 Sep 5;35(37):5019-5026. doi: 10.1016/j.vaccine.2017.07.068. Epub 2017 Jul 31.

PMID:
28774563
22.

Reply to Chung et al.

Skowronski DM, Chambers C, De Serres G.

J Infect Dis. 2017 Jul 15;216(2):285-287. doi: 10.1093/infdis/jix287. No abstract available.

PMID:
28633301
23.

Reduced Antibody Response to Infant Measles Vaccination: Effects Based on Type and Timing of the First Vaccine Dose Persist After the Second Dose.

Carazo Perez S, De Serres G, Bureau A, Skowronski DM.

Clin Infect Dis. 2017 Oct 1;65(7):1094-1102. doi: 10.1093/cid/cix510.

PMID:
28595358
24.

Repeated annual influenza vaccination and vaccine effectiveness: review of evidence.

Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.

Expert Rev Vaccines. 2017 Jul;16(7):1-14. doi: 10.1080/14760584.2017.1334554. Epub 2017 Jun 9. Review. Erratum in: Expert Rev Vaccines. 2017 Aug;16(8):865-866.

PMID:
28562111
25.

RE: "DETECTABLE RISKS IN STUDIES OF THE FETAL BENEFITS OF MATERNAL INFLUENZA VACCINATION".

De Serres G, Skowronski DM.

Am J Epidemiol. 2017 May 1;185(9):860-861. doi: 10.1093/aje/kww202. No abstract available.

PMID:
28369245
26.

Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis.

Boikos C, Papenburg J, Martineau C, Joseph L, Scheifele D, Chilvers M, Lands LC, De Serres G, Quach C.

Hum Vaccin Immunother. 2017 Jun 3;13(6):1-7. doi: 10.1080/21645515.2017.1287641. Epub 2017 Mar 8.

27.

Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada.

De Wals P, Deceuninck G, Lefebvre B, Tsang R, Law D, De Serres G, Gilca V, Gilca R, Boulianne N.

Clin Infect Dis. 2017 May 1;64(9):1263-1267. doi: 10.1093/cid/cix154.

PMID:
28207068
28.

Interim estimates of 2016/17 vaccine effectiveness against influenza A(H3N2), Canada, January 2017.

Skowronski DM, Chambers C, Sabaiduc S, Dickinson JA, Winter AL, De Serres G, Drews SJ, Jassem A, Gubbay JB, Charest H, Balshaw R, Bastien N, Li Y, Krajden M.

Euro Surveill. 2017 Feb 9;22(6). pii: 30460. doi: 10.2807/1560-7917.ES.2017.22.6.30460.

29.

Serial Vaccination and the Antigenic Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada, 2010-2011 to 2014-2015.

Skowronski DM, Chambers C, De Serres G, Sabaiduc S, Winter AL, Dickinson JA, Gubbay JB, Fonseca K, Drews SJ, Charest H, Martineau C, Krajden M, Petric M, Bastien N, Li Y, Smith DJ.

J Infect Dis. 2017 Apr 1;215(7):1059-1099. doi: 10.1093/infdis/jix074.

30.

Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement.

De Serres G, Skowronski DM, Ward BJ, Gardam M, Lemieux C, Yassi A, Patrick DM, Krajden M, Loeb M, Collignon P, Carrat F.

PLoS One. 2017 Jan 27;12(1):e0163586. doi: 10.1371/journal.pone.0163586. eCollection 2017.

31.

Clinical Approach Used in Medical Consultations for Allergic-Like Events Following Immunization: Case Series Report in Relation to Practice Guidelines.

Zafack JG, De Serres G, Rouleau I, Gariépy MC, Gagnon R, Drolet JP, Skowronski DM.

J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):718-727.e1. doi: 10.1016/j.jaip.2016.09.048. Epub 2016 Nov 30.

PMID:
27914816
32.

Do Dose Numbers Matter?: Evaluation of Differing Infant and Toddler Meningococcal C Conjugate Vaccine Programs in Canadian Children.

Bettinger JA, Vanderkooi OG, Scheifele DW, Halperin SA, Kellner JD, Schryvers A, De Serres G, Alcantara J.

Pediatr Infect Dis J. 2016 Nov;35(11):1242-1246.

PMID:
27753770
33.

Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings.

Boikos C, Joseph L, Martineau C, Papenburg J, Scheifele D, Lands LC, De Serres G, Chilvers M, Quach C.

Open Forum Infect Dis. 2016 Aug 30;3(4):ofw187. eCollection 2016 Oct.

34.

Immunizing Patients With Adverse Events After Immunization and Potential Contraindications to Immunization: A Report From the Special Immunization Clinics Network.

Top KA, Billard MN, Gariepy MC, Rouleau I, Pernica JM, Pham-Huy A, Quach C, Tran D, Vaudry W, Dobson S, Boucher FD, Carignan A, Jadavji T, McConnell A, McNeil SA, Halperin SA, De Serres G; Canadian Immunization Research Network’s (CIRN) Special Immunization Clinics Network investigators.

Pediatr Infect Dis J. 2016 Dec;35(12):e384-e391.

PMID:
27626920
35.

Repeat Influenza Vaccination and High-Dose Efficacy.

Skowronski DM, Chambers C, Gilca R, De Serres G.

Clin Infect Dis. 2016 Nov 1;63(9):1265-1266. Epub 2016 Aug 9. No abstract available.

PMID:
27506686
36.

A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Krajden M, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Kwindt TL, Bastien N, Li Y.

Clin Infect Dis. 2016 Jul 1;63(1):21-32. doi: 10.1093/cid/ciw176. Epub 2016 Mar 29.

37.

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.

De Wals P, Deceuninck G, De Serres G.

Vaccine. 2016 Apr 19;34(18):2053-4. doi: 10.1016/j.vaccine.2015.06.104. No abstract available.

PMID:
27021043
38.

Interim estimates of 2015/16 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, February 2016.

Chambers C, Skowronski DM, Sabaiduc S, Winter AL, Dickinson JA, De Serres G, Gubbay JB, Drews SJ, Martineau C, Eshaghi A, Krajden M, Bastien N, Li Y.

Euro Surveill. 2016;21(11):30168. doi: 10.2807/1560-7917.ES.2016.21.11.30168.

39.

Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers.

Top KA, Pham-Huy A, Price V, Sung L, Tran D, Vaudry W, Halperin SA, De Serres G.

Hum Vaccin Immunother. 2016 Apr 2;12(4):931-6. doi: 10.1080/21645515.2015.1115165. Epub 2016 Mar 10.

40.

Antigenic and genetic characterization of Bordetella pertussis recovered from Quebec, Canada, 2002-2014: detection of a genetic shift.

Shuel M, Lefebvre B, Whyte K, Hayden K, De Serres G, Brousseau N, Tsang RS.

Can J Microbiol. 2016 May;62(5):437-41. doi: 10.1139/cjm-2015-0781. Epub 2016 Jan 14.

PMID:
26910633
41.

Mutations acquired during cell culture isolation may affect antigenic characterisation of influenza A(H3N2) clade 3C.2a viruses.

Skowronski DM, Sabaiduc S, Chambers C, Eshaghi A, Gubbay JB, Krajden M, Drews SJ, Martineau C, De Serres G, Dickinson JA, Winter AL, Bastien N, Li Y.

Euro Surveill. 2016;21(3):30112. doi: 10.2807/1560-7917.ES.2016.21.3.30112.

42.

Systematic community- and hospital-based surveillance for enterovirus-D68 in three Canadian provinces, August to December 2014.

Skowronski DM, Chambers C, Sabaiduc S, Murti M, Gustafson R, Pollock S, Hoyano D, Rempel S, Allison S, De Serres G, Dickinson JA, Tellier R, Fonseca K, Drews SJ, Martineau C, Reyes-Domingo F, Wong T, Tang P, Krajden M.

Euro Surveill. 2015;20(43). doi: 10.2807/1560-7917.ES.2015.20.43.30047.

43.

Paresthesia and sensory disturbances associated with 2009 pandemic vaccine receipt: Clinical features and risk factors.

De Serres G, Rouleau I, Skowronski DM, Ouakki M, Lacroix K, Bédard F, Toth E, Landry M, Dupré N.

Vaccine. 2015 Aug 26;33(36):4464-71. doi: 10.1016/j.vaccine.2015.07.028. Epub 2015 Jul 22.

44.

Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015.

Gilca R, Skowronski DM, Douville-Fradet M, Amini R, Boulianne N, Rouleau I, Martineau C, Charest H, De Serres G.

PLoS One. 2015 Jul 22;10(7):e0132195. doi: 10.1371/journal.pone.0132195. eCollection 2015.

45.

Measles in Canada Between 2002 and 2013.

De Serres G, Desai S, Shane A, Hiebert J, Ouakki M, Severini A.

Open Forum Infect Dis. 2015 Apr 15;2(2):ofv048. doi: 10.1093/ofid/ofv048. eCollection 2015 Apr.

46.

Short- and Long-Term Effects of a Challenge Dose of Hepatitis B Vaccine in Individuals With and Without Residual Anti-HBs.

Gilca V, Boulianne N, Murphy D, De Serres G.

Infect Control Hosp Epidemiol. 2015 Sep;36(9):1119-20. doi: 10.1017/ice.2015.147. Epub 2015 Jun 25. No abstract available.

PMID:
26108991
47.

Dramatic reduction in hepatitis B through school-based immunization without a routine infant program in a low endemicity region.

Porgo TV, Gilca V, De Serres G, Tremblay M, Skowronski D.

BMC Infect Dis. 2015 Jun 12;15:227. doi: 10.1186/s12879-015-0979-8.

48.

Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.

Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P.

Vaccine. 2015 May 28;33(23):2684-9. doi: 10.1016/j.vaccine.2015.04.005. Epub 2015 Apr 15.

PMID:
25887086
49.

Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.

Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Winter AL, Dickinson JA, Gubbay J, Fonseca K, Charest H, Krajden M, Petric M, Mahmud SM, Van Caeseele P, Bastien N, Eshaghi A, Li Y.

J Infect Dis. 2015 Sep 1;212(5):726-39. doi: 10.1093/infdis/jiv177. Epub 2015 Mar 17.

PMID:
25784728
50.

Other respiratory viruses are important contributors to adult respiratory hospitalizations and mortality even during peak weeks of the influenza season.

Gilca R, Amini R, Douville-Fradet M, Charest H, Dubuque J, Boulianne N, Skowronski DM, De Serres G.

Open Forum Infect Dis. 2014 Sep 22;1(2):ofu086. doi: 10.1093/ofid/ofu086. eCollection 2014 Sep.

Supplemental Content

Loading ...
Support Center